抗發炎治療藥與市場:標的、技術、市場、策略、預測

Therapeutic Anti-Inflammatory Drugs & Markets: Targets, Technologies, Markets, Strategies, Forecasts

出版日期: 2022年12月31日 | 出版商:

Greystone Research Associates | 英文 107 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

已開發國家的平均壽命延長，隨著人口高齡化，慢性疼痛及急性疼痛的發生率關聯的罹患率增加，對患者與其家族來說作為QOL問題的疼痛管理變得更受到重視。

本報告提供抗發炎治療藥的市場調查，發炎性疾病概要，治療標的，法律制度，市場影響因素的分析，市場規模的變化、預測，市場佔有率，參與企業的簡介等資料。

The influence of immune mediators on inflammatory diseases has put the immune mediated therapeutics at the center of inflammatory disease treatment and management. The result is a growing list of approved and development-stage drugs designed to inhibit at least one of the fifteen pathway targets that drive the transcription and secretion of inflammatory cytokines into the extracellular space where they impact patient morbidity and inflammatory disease burden. The competitive landscape now includes more than two dozen drug developers. As this marketspace has evolved, the prime product opportunities, which we define as the drugability of individual pathway targets factored by the inverse of the number of competing drugs and late-stage candidates, has been shrinking. The distribution of therapeutic products in this segment varies across pathway elements, with 84 percent targeting signaling proteins and ligands, and receptors and transcription factors accounting for 8 percent each.

Targeting Key Inflammatory Pathways:

The identification of key immune mechanisms as causative for human inflammatory disease has led to the approval and rapid development of novel therapeutic agents.

Monoclonal antibodies to a variety of cytokines and cytokine receptors and small-molecule inhibitors of RORyt and JAKs are changing the therapeutic landscape, with three dozen distinct products now approved or in clinical development.

Humanized monoclonal antibodies to both IL-17 and IL-17RA are enabling improved outcomes for moderate to severe psoriasis as well as psoriatic arthritis.

What You Will Learn:

What are the immune factors that are responsible for immune mediated inflammatory Diseases?

What are the inflammatory-mediated ligands, receptors, signaling proteins and transcription factors that represent druggable targets?

What are the major factors driving the high level of development activity in immune mediated inflammatory diseases?

What is the size of the market today, who are the market share leaders?

What will be the effects of competing pathway solutions for the same indication and how will this dynamic impact revenue forecasts over the next four years?